Pharma IQ Members


Find out which informatics are right for your lab. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in pharmaceutical, biotech and life science laboratories to exchange ideas on best practice and share case studies on laboratory innovation and automation within the area.

Contributor: Paul Denny-Gouldson
Posted: 01/11/2016
Paul Denny-Gouldson
The meeting was kicked off by John Wise, Executive Director at Pistoia Alliance, who shared a delightful, anecdote-filled review of the current pharma R&D business landscape. In his talk, he gave detailed evidence of how different pharma companies were comparing the amount they spend to bring each new drug to market. He highlighted just ‘being big’ was not enough, and explained how a company’s approach to innovation also plays a role in the drug discovery process. Full Article »
Contributor: Gerald Clarke
Posted: 24/03/2014
The informatics landscape is changing quickly and innovation could be the key to increasing efficiency. Jeff Hurst, Senior Scientist at the Hershey's Company talks us through these changes and how the industry is moving away from robots towards more innovative methods including mobile apps. He also talks about the dangers of becoming overly ' Full Podcast »
Contributor: Andrew Love
Posted: 10/09/2014
Andrew Love
In the final article in his serialisation series, Andrew Love looks at what needs to be done to commence the development of your strategy and implementation of your solutions. Andrew outlines the challenges you are likely to face such as identifying and interpreting the emerging and evolving legislation or Understanding the immature and evolving solution supply base and selecting appropriate implementation partners. He outlines solutions to these problems to clear your path to serialisation implementation Full Column »
Contributor: Chanice Henry
Posted: 21/06/2016
Chanice Henry
The transition from paper to electronic Trial Master File (TMF) system, is a significant task, which is further complicated with the varying views and opinions complicating the route to standardisation. This is partially solved by the new directives under construction alongside the EMA’s updated information providing giving insight into inspector’s reviewing behaviours and what has been examined as of late for eTMFs. These much needed points of clarification help inform pharma and biotech companies on how to best create and maintain an eTMF system. Full Whitepaper »